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The increasing prevalence of ciprofloxacin-resistant
Neisseria gonorrhoeae has required replacing inexpensive
oral ciprofloxacin treatment with more expensive injectable
ceftriaxone. Further, monitoring antimicrobial resistance
requires culture testing, but nonculture gonorrhea tests are
rapidly replacing culture. Since the strategies were similar
in effectiveness (>99%), we evaluated, from the health-
care system perspective, cost-minimizing strategies for
both diagnosis (culture followed by antimicrobial suscepti-
bility tests versus nonculture-based tests) and treatment
(ciprofloxacin versus ceftriaxone) of gonorrhea in women.
Our results indicate that switching from ciprofloxacin to
ceftriaxone is cost-minimizing (i.e., optimal) when the
prevalence of gonorrhea is >3% and prevalence of
ciprofloxacin resistance is >5%. Similarly, culture-based
testing and susceptibility surveillance are optimal when the
prevalence of gonorrhea is <13%; nonculture-based test-
ing is optimal (cost-minimizing) when gonorrhea preva-
lence is >13%. 
G
onorrhea is the second most frequently reported sexu-
ally transmitted disease (STD) in the United States
(1,2) infecting an estimated 800,000 people at a cost of $1
billion annually (3,4). In women, untreated gonorrhea can
lead to pelvic inflammatory disease (PID) and to profound
long-term sequelae such as chronic pelvic pain, ectopic
pregnancy, and infertility (5). In addition, gonococcal
infections have been shown to facilitate transmission of
HIV (6). Gonorrhea is frequently asymptomatic in women,
which creates a large pool of undetected infections. These
infections go untreated, which may increase the probabili-
ty of disease progression in the patient and transmission to
sexual partners.
An important obstacle in the control of gonorrhea is the
emergence of antimicrobial–resistant strains. As cipro-
floxacin-resistant  Neisseria gonorrhoeae strains become
more prevalent in the United States (7–10),treatment with
cephalosporins such as cefixime and ceftriaxone becomes
necessary (10,11). Antimicrobial susceptibility testing
requires that N. gonorrhoeae be grown in  culture.
However, the availability of affordable and accurate non-
culture tests, along with the convenience of combination
nonculture tests for N. gonorrhoeae and Chlamydia tra-
chomatis, has resulted in the increased use of nonculture-
based tests1 (12). The resulting reduction in the use of
culture-based testing poses challenges for monitoring
antimicrobial resistance. 
To the best of our knowledge, the economic conse-
quences of diagnostic test and treatment selection in the
face of rising antimicrobial resistance for N. gonorrhoeae
have not been explored in the literature. Our objective was
to identify the most cost-effective combination of diagnos-
tic test (culture or nonculture) and treatment (ciprofloxacin
or ceftriaxone) for gonorrhea when the incidence of
ciprofloxacin-resistant  N. gonorrhoeae infections is
increasing.
Methods
The 4 Strategies
We evaluated and compared the cost and disease out-
comes associated with 4 strategies, identified from current
practice and consultations with experts, for diagnosing and
treating gonorrhea in women (Table 1). The 2 treatments
evaluated were a single, oral 500-mg dose of ciprofloxacin
(for which gonococcal resistance exists in some parts of the
United States), and a single, 125-mg dose of ceftriaxone by
intramuscular injection (for which we assumed no resist-
ance has been identified). Two of the strategies used
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1In 2000, only 18% of gonorrhea tests performed by public health
laboratories in the United States were culture-based tests.culture-based tests followed by antimicrobial susceptibility
testing, while the remaining 2 strategies used nonculture-
based combination tests, such as nucleic acid amplification
assay or the nucleic acid hybridization test, for detecting
both N. gonorrhoeae and C. trachomatis. Since we know
that resistance to ciprofloxacin already exists, we assume
that 80% of culture-positive specimens would also be test-
ed for antimicrobial susceptibility when ciprofloxacin was
used for treatment (ST1). Ideally, 100% of culture-positive
specimens would be tested for antimicrobial susceptibility,
but we allow for some losses because of incomplete track-
ing, handling, and transportation. In the absence of record-
ed treatment failure caused by antimicrobial resistance to
ceftriaxone, we assume that 20% of specimens would be
susceptibility tested for surveillance purposes. 
For all 4 strategies, we assume that women with symp-
toms of gonorrhea who go to a healthcare provider will be
presumptively treated with the antimicrobial agent indicat-
ed by the strategy. In all strategies, all women undergo
testing for gonorrhea with either culture- or nonculture-
based tests. All strategies assume that attempts will be
made to recall and treat asymptomatic women who test
positive. Two strategies (ST1 and ST3, Table 1) further
assume that those symptomatic women found to be infect-
ed by a resistant strain will be recalled and retreated.
Successful treatment of the detected patients depends on
the effectiveness of the antimicrobial therapy, given the
particular susceptibility patterns of gonococcal strains in a
geographic location.
Economic Evaluation Methods
To conduct an economic evaluation of the 4 strategies
from a healthcare system perspective, we built a decision
tree by using DATA 4.0 (TreeAge Software Inc.,
Williamstown, MA, USA). Online Appendix 1 contains
schematics of the tree (http://www.cdc.gov/ncidod/EID/
vol11no08/05-0157_app1.htm). The gonorrhea-related
health outcomes included in the evaluation of each strate-
gy were PID and PID-associated sequelae (chronic pelvic
pain, ectopic pregnancy, and infertility). We also included
the probability and associated costs of female-to-male
transmission of gonorrhea (assuming that all couples are
heterosexual). If the male partner is infected, either ure-
thritis or epididymitis could develop and the infection
could be transmitted to another female partner (or the
original female partner could be reinfected after she has
been cured of the initial infection). In the initial female-to-
male transmission of gonorrhea, the additional probabili-
ty and associated costs of cotransmission of HIV exist.
Economic outcomes include all diagnostic test-related
costs (i.e., cost of supplies, equipment, and labor), direct
medical costs of treatment (for pelvic examination and
patient recall), cost of treating PID and sequelae (i.e.,
inpatient and outpatient medical costs), and costs of trans-
mission of gonorrhea and HIV to sex partners (assuming
that all couples are heterosexual).
For each strategy (Table 1), we used the decision tree to
calculate the expected cost per case of gonorrhea treated,
the expected proportion of cases successfully treated
(case-patients with no PID or sequelae), and expected cost
per case-patient successfully treated. Average and incre-
mental cost-effectiveness analyses, also conducted for a
hypothetical cohort of 1 million women treated with each
of the 4 alternative strategies, are contained in online
Appendix 2 (http://www.cdc.gov/ncidod/EID/vol11no08/
05-0157_app2.htm). 
Data
Probabilities 
The probabilities used were derived from a review of
the published literature, expert opinion, and unpublished
data from local, state, and national sources (Table 2). In the
base case, the prevalence of gonococcal infection among
women was assumed to be 0.5% (range 0%–15%). We
assumed that of all gonorrhea-infected women who enter
the clinic, 30% (range 20%–60%) display urogenital
symptoms for gonorrhea, and 70% do not display such
symptoms. We also assume among women who enter the
clinic, but are uninfected with gonorrhea, that 20% (range
0%–40%) will be presumptively treated for gonorrhea due
to nonspecific urogenital symptoms associated with both
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untreated cases of gonorrhea have a 16% probability of
developing PID (15,16).
Previous studies used an estimate that 80% of women
notified of a positive test result returned for treatment
(16,17). However, in the absence of additional supportive
data, we assumed recall rates, for both asymptomatic
patients and those infected with a resistant strain, to be
40%. To simplify the model, we further assumed that
infection with a resistant strain would lead to complete
treatment failure. In reality, antimicrobial resistance is
often not absolute, and successful treatment may still occur
when a patient is infected with a resistant strain. This
assumption biases the results toward switching from
ciprofloxacin to ceftriaxone (i.e., from ST1 or ST2 to ST3
or ST4, Table 1). The sensitivity and specificity of the sev-
eral screening tests were obtained from the peer-reviewed
medical literature (14,18,19). 
Costs
Table 3 shows the cost estimates used in the model. The
direct medical costs included were those associated with
diagnostic testing, antimicrobial therapy for gonorrhea,
and subsequent sequelae of untreated gonorrhea
(15,21–23). Because the perspective of the analysis is that
of the healthcare system, we did not include indirect costs,
such as lost production, and intangible costs, such as pain
and personal trauma.
Previous studies estimated the average clinician time
associated with a full pelvic examination, including the
Optimizing Treatment of Neisseria gonorrhoeae
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 8, August 2005 1267estimated follow-up cost of scheduling a return visit for a
positive test result, by direct observation of activities in a
clinic patient-flow analysis (17). The direct medical costs
of the time associated with a PID-related clinic visit, either
an initial visit or one including a full pelvic exam, were
estimated by using the MarketScan database (24). The costs
of the various diagnostic tests were obtained through per-
sonal communication with health department laboratories
in Hawaii, Orange County (California), and Florida (Table
3). The cost of diagnostic tests included the cost of
reagents, kits, equipment, supplies, and the laboratory
technician’s time. For nonculture tests, since N. gonor-
rhoeae testing is routinely performed as part of a dual N.
gonorrhoeae and C. trachomatis test, the incremental cost
of performing the N. gonorrhoeae test as part of the dual
test was used in the base model. However, the consider-
ably higher cost of performing a single N. gonorrhoeae
nonculture test by itself was incorporated and examined in
the sensitivity analysis. The range of costs for antimicro-
bial agents reflects the prices obtained from both the pri-
vate sector and public clinics (25,26). We assume directly
observed therapy resulting in full treatment compliance,
and any residual noncompliance is implicitly assumed as
treatment failure. We estimated the average cost of both
symptomatic and asymptomatic PID by summing the costs
associated with each outcome multiplied by the proportion
of persons who will be affected (Table 3). The principal
outcomes associated with untreated infection, if sympto-
matic, include inpatient and outpatient treatment cost of
PID and subsequent long-term chronic pelvic pain, sur-
gery, ectopic pregnancy, and infertility. The outcomes
associated with asymptomatic or silent PID are long-term
sequelae only. The model also incorporated the cost of
transmission of both gonorrhea and HIV to the index
patient’s sexual partners (20,27,28). All cost data were
adjusted to 2001 US dollars, by using the medical care
component of the consumer price index (29).
Sensitivity Analysis
Univariate sensitivity analyses were conducted to
examine the effect of changes in the prevalence of gonor-
rhea and the prevalence of ciprofloxacin-resistant N. gon-
orrhoeae  on the cost per patient successfully treated.
Multivariate sensitivity analyses were conducted to deter-
mine breakeven points (or threshold values) indicating
input values at which any 2 strategies had the same cost
per patient successfully treated. Threshold values were cal-
culated to determine the robustness of the baseline results
and the relative importance of the input variables on allow-
ing for variation around the baseline.
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simultaneously changed the values of key variables over a
range of gonorrhea prevalence in women (0%–15%) and a
range of prevalence of ciprofloxacin-resistant gonorrhea
(0%–20%). We changed the cost ratio of ciprofloxacin to
ceftriaxone from the base case of 1:5 (ciprofloxacin =
$2/dose; ceftriaxone = $10/dose; Table 3) to both 1:2 and
1:7.5. Simultaneously, we changed the cost ratio of culture
tests to nonculture tests from 1:1.4 (culture tests = $5, non-
culture tests = $5, Table 3) to both 1:1 and 1:3. We then
simultaneously altered the specificity and sensitivity of the
2 tests. Finally, we conducted a Monte Carlo simulation,2
in which we simultaneously altered all the input variables
by using predefined probability distributions to examine
whether they had significant consequences on model
results.
Results 
Base Case Analysis
All 4 strategies ensured that PID did not develop in
>99% of all treated patients, regardless of the assumed
prevalence of gonorrhea (Table 4). This finding means that
the costs per patient treated are almost the same as the cost
per patient successfully treated (i.e., costs per patient with
no PID or sequelae) and that relative costs are central in
determining cost-effectiveness. However, the high cost-
effectiveness ratios (CERs, which estimate the additional
cost per additional case of PID averted on comparing a
strategy with the baseline or the next-most-effective strate-
gy in average and incremental cost-effectiveness analysis,
respectively) generated in cases in which alternative strate-
gies are similar in effectiveness do not offer an intuitive
decision-making tool for choosing an optimal strategy.
Instead, a cost-minimization approach, which selects as
optimal a strategy that minimizes cost per case successful-
ly prevented (i.e., least costly in achieving the same level of
effectiveness), provides a more practical and intuitive deci-
sion-making tool. Detailed results from incremental cost-
effectiveness analyses are contained in online Appendix 2
for those programs that choose to consider the additional
CERs in making decision on budgetary allocations.
When the prevalence of gonorrhea is <5%, the 2 strate-
gies based on culture and susceptibility testing (ST1 and
ST3) are cheaper than the other 2 strategies (ST2 and
ST4). For any strategy, increasing the prevalence of gonor-
rhea from 1% to 10% more than doubled the cost per
patient treated. This doubling is primarily due to the
increase in the proportion of patients who face additional
costs for testing, treatment, or both.
Results from varying the prevalence of gonorrhea and
the prevalence of ciprofloxacin resistance simultaneously
are shown in Figure 1. If the prevalence of gonorrhea is
<1%, ST1 has the lowest cost per patient successfully treat-
ed even if prevalence of ciprofloxacin resistance is as high
as 20%. Even when prevalence of gonorrhea approaches
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2Monte Carlo simulation involves specifying a probability distribu-
tion of values for model inputs. A computer algorithm then runs the
model for several iterations. During each iteration, the computer
algorithm selects input values from the probability distributions,
and calculates the output (e.g., cost per patient successfully treat-
ed). After the final run, the model provides results such as the
mean, median, and 5th and 95th percentiles for each specified
output.3%, ST1 is the optimal strategy if prevalence of
ciprofloxacin resistance is <4%. Strategy 3 (ceftriaxone +
culture-based testing) is frequently the most optimal strate-
gy when prevalence of gonorrhea is 3%–12%. With a few
exceptions, the 2 strategies that use nonculture-based tests
become most optimal only when the prevalence of gonor-
rhea is >13%. Finally, if ciprofloxacin-resistance levels are
>3% and gonorrhea prevalence is >13%, a switch to
ceftriaxone (ST4) is recommended. Overall, the base-case
analysis indicates that culture-based strategies are optimal
(lowest cost per patient successfully treated) at lower levels
of gonorrhea prevalence, while nonculture-based strategies
become optimal as gonorrhea prevalence increases. 
Sensitivity Analysis
The model was found to be sensitive to changes in sev-
eral estimates, including the relative cost of antimicrobial
agents and diagnostic tests. For example, if the ratio of cost
of ciprofloxacin to cost of ceftriaxone is changed from 1:5
(base case, Figure 1) to 1:2 (Figure 2A) and the costs of
tests become equal (Figure 2A), the two strategies that
include non-culture tests (ST2 and ST4) are optimal for
greater combinations of gonorrhea prevalence and
ciprofloxacin-resistance prevalence than in the base case.
However, if the ratio of the cost of culture tests to non-cul-
ture tests is changed from 1:1 (Figure 2A) to 1:3 (Figure
2B), then the two strategies that include culture tests (ST1
and ST3) become optimal for all combinations of gonor-
rhea prevalence and ciprofloxacin-resistance prevalence. 
Regardless of the relative difference in sensitivity and
specificity of the 2 types of tests, strategies containing
culture-based tests (ST1 or ST3) are optimal if prevalence
of gonorrhea is <6% (Figure 3A). However, when both
the sensitivity and specificity of the culture-based tests are
set at the minimum values, and the nonculture-based tests
are at maximum values, the optimal diagnostic choice
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Figure 1. Lowest cost per patient successfully treated on varying
prevalence of gonorrhea and prevalence of ciprofloxacin-resistant
Neisseria gonorrhoeae. Notes: strategy depicted is optimal (lowest
cost per patient successfully treated) for given combinations of
prevalence of gonorrhea and prevalence of ciprofloxacin-resistant
N. gonorrhoeae. Since the alternative strategies are similar in
effectiveness, cost-effectiveness analysis does not offer a practi-
cal decision-making tool. Instead, cost minimization, which selects
as optimal a strategy that costs least while achieving the same
level of effectiveness (i.e., per case of successful treatment),
serves as a more practical and intuitive tool kit for decision mak-
ing. Case-patients refer to all women who attend a public health
clinic and undergo therapy as per 1 of the 4 strategies, regardless
of actual infection. The strategies modeled were ST1: ciprofloxacin
+ culture-based tests + ciprofloxacin-susceptibility tests; ST2:
ciprofloxacin + nonculture-based tests; ST3: ceftriaxone + culture-
based tests + ceftriaxone-susceptibility tests; ST4: ceftriaxone +
nonculture-based tests (see Table 1 and text for further details).
Values for input variables other than prevalence of gonorrhea and
prevalence of ciprofloxacin-resistant N. gonorrhoeae are the base
case values given in Tables 2 and 3.
Figure 2. Lowest cost per patient successfully treated on varying
relative costs of drugs and tests. A) Cost of culture = $5; cost of
nonculture = $5; cost of ciprofloxacin= $5; cost of ceftriaxone =
$10. B) Cost of culture = $5; cost of nonculture = $15; cost of
ciprofloxacin = $2; cost of ceftriaxone=$15. For notes, see
Figure 1 legend. 
A
Bswitches from culture-based (ST1 or ST3) to nonculture-
based tests (ST2 or ST4), if prevalence of gonorrhea is
>8% (Figures 3A). However, when the sensitivity and
specificity of culture-based tests are set at their maximum
value, and the nonculture-based tests are at their minimum
value, the 2 strategies that contain culture-based tests are
optimal for all combinations of gonorrhea prevalence and
ciprofloxacin-resistance prevalence (Figure 3B).
From the Monte Carlo analysis, for 3 of the combina-
tions of gonorrhea prevalence and ciprofloxacin-resistance
prevalence, strategy 1 has the lowest mean cost per patient
treated (Table 5). Only when gonorrhea prevalence is 2%
and ciprofloxacin-resistance prevalence is 10% does strat-
egy 3 have a lower mean cost per patient treated (Table 5).
Note that, for any given combination of gonorrhea preva-
lence and ciprofloxacin-resistance prevalence, consider-
able overlap exists among the confidence intervals around
the means of the cost per patient treated (Table 5).
Discussion 
The absence of any recommended, evidence-based
method that can be used to identify the most cost-effective
gonorrhea treatment strategy has resulted in ad hoc deci-
sion making regarding when to change drug therapy
because of antimicrobial resistance. For example, the
threshold for changing drug therapy for gonorrhea treat-
ment has often been when prevalence of gonococcal
strains resistant to a given antimicrobial agent reaches 5%
(30–32).The model indicates that using a single variable to
define the breakpoint is inefficient. For example, if gonor-
rhea prevalence is <1%, our results show that
ciprofloxacin would be most optimal even if ciprofloxacin
resistance were as high as 20%. The decision regarding
when to change from 1 drug to another on the basis of the
prevalence of gonorrhea and the prevalence of
ciprofloxacin resistance is summarized in a tool kit con-
tained in online Appendix 3 (http://www.cdc.gov/ncidod/
EID/vol11no08/ 05-0157_app3.htm).
While we cannot cover every situation and setting, our
results clearly illustrate that a single, generic policy
regarding when to switch drug treatments (for reasons of
antimicrobial resistance) is not necessarily optimal from
an economic perspective. However, the sensitivity analy-
ses demonstrate that our model has wide applicability and
can, by varying input data, provide answers across a wide
range of settings. The current model can readily be adopt-
ed to produce a practical and interactive tool kit that would
allow for variation across a wide range of input values.
Our analyses identified 2 other important points. First,
since all the strategies were similar in terms of effective-
ness (i.e., percentage of patients successfully treated), rel-
ative costs will be important in determining the most
cost-effective strategy. Second, the large variability in key
variables (i.e., prevalence of gonorrhea, prevalence of
ciprofloxacin-resistance, relative costs of drugs and diag-
nostic tests) across geographic locations and clinical set-
tings makes it unlikely that the same single strategy will be
the most cost-effective strategy across all these settings. 
The sensitivity of the results to relative costs of diag-
nostic tests is of concern because the current practice of
providing higher reimbursement rates (compared to actual
cost) for nonculture serves as a subsidy for nonculture
tests. We also did not value all the benefits associated with
culture-based tests, specifically the additional knowledge
obtained regarding antimicrobial susceptibility. In inter-
preting the model results, the inadequacies of not account-
ing for the full benefits of culture should be acknowledged.
Likewise, nonculture-based testing, which does not neces-
sarily require a pelvic examination, may confer both cost
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Figure 3. Lowest cost per patient successfully treated on varying
sensitivity and specificity of culture- and nonculture-based tests.
A) Culture: sensitivity = 75%, specificity = 95%; nonculture: sensi-
tivity = 85%, specificity = 95%. For notes, see Figure 1 legend. B)
Culture: sensitivity = 95%, specificity = 97%; nonculture: sensitivi-
ty = 85%, specificity = 95%. 
A
Badvantages and higher patient acceptability (e.g., noninva-
sive methods for testing may be preferred by some
women).
Further, in practice, selection of diagnostic test is often
driven by priorities of testing for chlamydia, rather than
gonorrhea testing alone. We did not consider all the costs
and benefits associated with diagnosis and treatment of
both N. gonorrhoeae and C. trachomatis. In addition, our
results apply specifically to adult women and cannot be
generalized for men.
With regard to antimicrobial drug selection, Monte
Carlo simulations, which were based on assumed distribu-
tions and not actual data, show considerable overlap in
costs and effectiveness across the 2 antimicrobial choices.
Accordingly, caution should be exercised in recommend-
ing 1 drug over another, unless the results are backed with
more certain and site-specific data on key variables for a
given location.
A limitation that should prevent overemphasizing the
sensitivity of the results to the relative cost of the drugs is
the assumption of 100% treatment failure with
ciprofloxacin resistance, which may overestimate the cost
of ciprofloxacin resistance and incomplete patient recalls.
Our model also assumes that resistance (or other treatment
failures) to ceftriaxone is zero (as per the latest surveil-
lance reports), although the model is designed to allow one
to relax the assumption and vary the prevalence of ceftri-
axone resistance. If one were to assume <100% treatment
failure with ciprofloxacin or assume existence of some
treatment failure to ceftriaxone including resistance, using
ciprofloxacin (ST1 and ST2) would be most cost-effective
for even larger ranges of gonorrhea prevalence and
ciprofloxacin-resistance prevalence. 
If a single strategy has a greater probability of contribut-
ing to resistance (because of inappropriate antimicrobial
use), measuring the additional cost of increased resistance
is beyond the scope of this model. A model limitation also
arises from not including a valuation for reserving a class of
antimicrobial agents for future use. Our model contains the
implicit assumption that when ceftriaxone-resistant gonor-
rhea becomes problematic, an equally effective and afford-
able antimicrobial agent will be available to replace
ceftriaxone. If the future costs of prematurely depriving
physicians and patients of ceftriaxone were included, strat-
egy 1 would become the dominant strategy in Figure 1. Any
method used to recommend systemwide switching of
therapies because of antimicrobial resistance should take
into account that considerable value exists in keeping in
reserve an already existing antimicrobial agent for as long
as economically feasible. 
The overall conclusion from our model is that decisions
regarding changes in drug therapies used for gonorrhea
treatment require several types of data. Both prevalence of
gonorrhea and prevalence of ciprofloxacin-resistant gono-
coccal strains must be considered. Since prevalence data
are dynamic and population-specific, ongoing collection of
such data is necessary to allow informed decision making
to take place. 
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